Kyverna Therapeutics (KYTX) Liabilities and Shareholders Equity (2023 - 2026)

Kyverna Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $257.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.39% year-over-year to $257.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $964.5 million (down 23.91% YoY) and the FY2025 annual result came in at $293.8 million, down 3.55% from the prior year.
• Liabilities and Shareholders Equity was $257.0 million for Q1 2026 at Kyverna Therapeutics, down from $293.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $390.0 million in Q1 2024 and bottomed at $75.2 million in Q4 2023.
• A 4-year average of $269.7 million and a median of $277.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 305.14% — and 2025, when it slumped 44.82%.
• Kyverna Therapeutics' Liabilities and Shareholders Equity stood at $75.2 million in 2023, then jumped by 305.14% to $304.6 million in 2024, then fell by 3.55% to $293.8 million in 2025, then slipped by 12.53% to $257.0 million in 2026.
• Business Quant data shows KYTX's Liabilities and Shareholders Equity at $257.0 million in Q1 2026, $293.8 million in Q4 2025, and $187.2 million in Q3 2025.